- Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW171, a novel 2+1 T-cell Targeting Bispecific Antibody for Mesothelin-expressing Cancers
- Zymeworks Announces China NMPA Acceptance of Biologics License Application for Zanidatamab for Second-Line Treatment of Biliary Tract Cancer
- Zymeworks Announces Participation in Upcoming Investor Conferences
- Zymeworks Provides Corporate Update and Reports First Quarter 2024 Financial Results
- Zymeworks To Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024
- Zymeworks Presents New Data from Multiple Preclinical Development Programs at 2024 American Association for Cancer Research Annual Meeting
- Zymeworks Announces Appointment of Dr. Neil Gallagher to its Board of Directors
- Zymeworks Reports Fourth Quarter and Full Year 2023 Financial Results
- Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate and Multispecific Platforms at the American Association for Cancer Research Annual Meeting
- Zymeworks To Host Fourth Quarter and Full Year 2023 Results Conference Call
More ▼
Key statistics
On Friday, Zymeworks Inc (ZYME:NSQ) closed at 8.88, 47.63% above the 52 week low of 6.02 set on Oct 04, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 8.38 |
---|---|
High | 8.89 |
Low | 8.33 |
Bid | 8.60 |
Offer | 8.98 |
Previous close | 8.39 |
Average volume | 555.38k |
---|---|
Shares outstanding | 70.70m |
Free float | 66.21m |
P/E (TTM) | -- |
Market cap | 627.86m USD |
EPS (TTM) | -1.79 USD |
Data delayed at least 15 minutes, as of Jul 05 2024 21:00 BST.
More ▼